Clinical Trial Detail

NCT ID NCT04421963
Title Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib (ROSY-O)
Recruitment Not yet recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

endometrioid ovary carcinoma

ovarian serous carcinoma

Therapies

Olaparib

Age Groups: adult senior

No variant requirements are available.